We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EFOR:BISTEfor Yatirim Sanayi Ticaret A.S. Analysis

Data as of 2026-09-10 - not real-time

$30.33

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Everforth, Inc. is priced at $30.33, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 29.6%. With RSI at 50.8 the momentum picture is neutral, alongside a bearish MACD signal. The recent range runs from support at $29.71 up to resistance at $33.78.
Multiples put this in undervalued territory: 15.6 times earnings against the sector's 32.9. The average analyst target implies 9.3% below today's level.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 63.5%, a beta of 0.92 and a maximum drawdown of 68.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.

Top Market Events

In late July 2026, Everforth, Inc. reported second-quarter results showing year-on-year declines in sales and net...GLEN ALLEN, Va. AP — GLEN ALLEN, Va. AP — Everforth, Inc. EFOR on Wednesday reported net income of $14.2 million in...Seeking Alpha1monEverforth, Inc. EFOR Q2 2026 Earnings Call TranscriptGreetings. Welcome to the Everforth Second...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 34.13
  • MACD momentum is negative
  • 30-day price change of +29.6%

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 15.6 versus sector average of 32.9
  • Trading below the 200-day average of 34.13
  • Analyst targets imply -9.3% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 15.6 versus sector average of 32.9
  • Analyst targets imply -9.3% versus the current price
  • Revenue contracting at -1.3%

Key Metrics & Analysis

Financial Health

Revenue Growth-1.30%
Profit Margin2.09%
P/E Ratio15.6
ROE4.57%
ROA3.79%
Debt/Equity82.91
P/B Ratio0.7
Op. Cash Flow$256.9M
Free Cash Flow$213.5M
Industry P/E32.9

Technical Analysis

TrendNeutral
RSI50.8
Support$29.71
Resistance$33.78
MA 20$31.63
MA 50$26.46
MA 200$34.13
MACDBearish
VolumeIncreasing
Fear & Greed Index90.45

Valuation

Fair Value$32.88
Target Price$27.50
Upside/Downside-9.33%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.92
Volatility63.54%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.